ウイルス不活性化市場：製品、方法、用途、エンドユーザー別-2025-2030年の世界予測

ウイルス不活性化市場は、2023年に9億7,741万米ドルと評価され、2024年には11億1,948万米ドルに達すると予測され、CAGR 14.62%で成長し、2030年には25億4,174万米ドルに達すると予測されています。

ウイルス不活性化は、生物製剤、ワクチン、血液製剤に含まれる潜在的なウイルス汚染物質を中和するために設計された、バイオ医薬品製造およびヘルスケアにおける重要なプロセスです。このプロセスは、医薬品の安全性と有効性を確保し、公衆衛生を守るために不可欠です。さらに、その用途は医薬品、バイオテクノロジー、輸血、診断研究所など様々な分野に及び、最終用途は病院、診断センター、研究機関などです。市場の主な原動力は、生物学的安全性に関する規制基準の高まりと、効果的で安全な治療薬に対する需要の高まりです。さらに、溶媒／洗剤処理、低温殺菌、低pH処理、UV照射などの技術が進歩し、信頼性の高いウイルス不活性化が可能になったことも成長を後押ししています。さらに、慢性疾患の蔓延が深刻化し、個別化医療への注目が高まっていることも、ウイルス不活性化アプリケーションの可能性を広げています。しかし、運用コストの高さ、技術的な複雑さ、厳しい規制遵守などの課題が、市場の成長を妨げる可能性があります。特に新興経済諸国では、さまざまな規制やインフラの格差により、市場は地理的な制約に直面しています。ビジネスチャンスは、革新的技術の採用や、適用範囲を広げプロセス効率を高めることができるマルチモーダル不活化プラットフォームの開発にあります。より効率的で費用対効果の高い手法や、より新しい耐性ウイルス株に対応できる技術の調査は、成長を促進するために不可欠です。企業は、こうした機会を効果的に活用するために、戦略的パートナーシップと研究開発への投資を優先すべきです。市場が有望であるにもかかわらず、複雑な規制状況や、プロセスによる変質が製品の品質に悪影響を及ぼす可能性は、依然として大きなハードルとなっています。全体として、技術革新を通じて先手を打ち、費用対効果を確保しながら進化する規制基準に適応していくことが、ウイルス不活性化市場での成功を目指す企業にとって重要な戦略です。

市場力学：急速に進化するウイルス不活性化市場の主要市場インサイトを公開

ウイルス不活性化市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の世界の増加
  • 製薬・バイオテクノロジー産業に対する政府支援の拡大
  • 新薬承認数の増加
• 市場抑制要因
  • バイオシミラー製品の製造に関連する高コスト
• 市場機会
  • ウイルス不活性化手順における技術統合
  • ライフサイエンス業界における旺盛な研究開発投資
• 市場の課題
  • 政府の厳しい規制ガイドライン

ポーターの5つの力：ウイルス不活性化市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ウイルス不活性化市場における外部からの影響の把握

外部マクロ環境要因は、ウイルス不活性化市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ウイルス不活性化市場における競合情勢の把握

ウイルス不活性化市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスウイルス不活性化市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ウイルス不活性化市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ウイルス不活性化市場における成功への道筋を描く

ウイルス不活性化市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の世界的蔓延
    • 製薬・バイオテクノロジー産業に対する政府の支援拡大
    • 新薬承認数の増加
  • 抑制要因
    • バイオシミラー製品の製造に伴う高コスト
  • 機会
    • ウイルス不活性化手順における技術統合
    • ライフサイエンス業界への強力な研究開発投資
  • 課題
    • 厳格な政府の規制ガイドライン
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ウイルス不活性化市場：製品別

• キットと試薬
• サービス
• ウイルス不活性化システムとアクセサリ

第7章 ウイルス不活性化市場：方法別

• 殺菌
• 溶剤洗剤法

第8章 ウイルス不活性化市場：用途別

• 血液および血液製品
• 細胞・遺伝子治療製品
• 幹細胞製品
• ティッシュおよびティッシュ製品
• ワクチンと治療

第9章 ウイルス不活性化市場：エンドユーザー別

• 学術調査機関
• 契約調査機関
• 製薬・バイオテクノロジー企業

第10章 南北アメリカのウイルス不活性化市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のウイルス不活性化市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのウイルス不活性化市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories International, Inc.
• Cytiva by Danaher Corporation
• Eurofins Scientific（Ireland）Limited
• HiMedia Laboratories, LLC
• Lonza Group Ltd.
• Merck KGaA
• Parker Hannifin Corporation
• PromoCell GmbH
• Rad Source Technologies, Inc.
• Sartorius AG
• Thermo Fisher Scientific Inc
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. VIRAL INACTIVATION MARKET RESEARCH PROCESS
• FIGURE 2. VIRAL INACTIVATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. VIRAL INACTIVATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. VIRAL INACTIVATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VIRAL INACTIVATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VIRAL INACTIVATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VIRAL INACTIVATION MARKET DYNAMICS
• TABLE 7. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VIRAL INACTIVATION SYSTEMS & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PASTEURIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY SOLVENT DETERGENT METHOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY BLOOD & BLOOD PRODUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CELLULAR & GENE THERAPY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY STEM CELL PRODUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY TISSUES & TISSUE PRODUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY VACCINES & THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL VIRAL INACTIVATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CANADA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 39. CANADA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES VIRAL INACTIVATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. CHINA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. CHINA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 61. CHINA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. INDIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. INDIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 65. INDIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. ITALY VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. ITALY VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 134. ITALY VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. POLAND VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. POLAND VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 150. POLAND VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. QATAR VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. QATAR VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 154. QATAR VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM VIRAL INACTIVATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. VIRAL INACTIVATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. VIRAL INACTIVATION MARKET, FPNV POSITIONING MATRIX, 2023

The Viral Inactivation Market was valued at USD 977.41 million in 2023, expected to reach USD 1,119.48 million in 2024, and is projected to grow at a CAGR of 14.62%, to USD 2,541.74 million by 2030.

Viral inactivation is a critical process in biopharmaceutical manufacturing and healthcare, designed to neutralize potential viral contaminants in biologics, vaccines, and blood products. This process is essential for ensuring the safety and efficacy of pharmaceutical products, thereby protecting public health. Moreover, its application spans various fields, including pharmaceuticals, biotechnology, blood transfusion, and diagnostic laboratories, with end-use sectors comprising hospitals, diagnostic centers, and research institutions. The market is primarily driven by increasing regulatory standards for biologic safety and the rising demand for effective and safe therapeutics. Growth is further propelled by advancements in technologies such as solvent/detergent treatment, pasteurization, low pH treatment, and UV irradiation, enabling reliable viral inactivation. Additionally, the escalating prevalence of chronic diseases and increased focus on personalized medicine have expanded the potential for viral inactivation applications. However, challenges such as high operational costs, technical complexities, and stringent regulatory compliance may hamper market growth. The market faces geographical limitations due to varying regulations and infrastructure disparities, particularly in developing economies. Opportunities lie in adopting innovative technologies and developing multimodal inactivation platforms, which can broaden applicability and enhance process efficiency. Research into more efficient, cost-effective methods, and technologies that can handle newer and more resistant viral strains are imperative for driving growth. Companies should prioritize strategic partnerships and investment in R&D to harness these opportunities effectively. Despite the promising nature of the market, the intricate regulatory landscape and the possible adverse effects on product quality due to process-induced alterations remain significant hurdles. Overall, staying ahead through innovation and adapting to evolving regulatory standards while ensuring cost-effectiveness are key strategies for businesses aiming to thrive in the viral inactivation market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Inactivation Market

The Viral Inactivation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the global prevalence of chronic diseases
  • Growing government support for pharmaceutical & biotechnology industries
  • Rising number of new drug approvals
• Market Restraints
  • High costs associated with the manufacture of biosimilar products
• Market Opportunities
  • Technological integrations in viral inactivation procedures
  • Strong R&D investments in the life sciences industry
• Market Challenges
  • Strict government regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Viral Inactivation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Inactivation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Inactivation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Inactivation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Inactivation Market

A detailed market share analysis in the Viral Inactivation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Inactivation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Inactivation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Viral Inactivation Market

A strategic analysis of the Viral Inactivation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Viral Inactivation Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Cytiva by Danaher Corporation, Eurofins Scientific (Ireland) Limited, HiMedia Laboratories, LLC, Lonza Group Ltd., Merck KGaA, Parker Hannifin Corporation, PromoCell GmbH, Rad Source Technologies, Inc., Sartorius AG, Thermo Fisher Scientific Inc, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Viral Inactivation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Kits & Reagents, Services, and Viral Inactivation Systems & Accessories.
• Based on Method, market is studied across Pasteurization and Solvent Detergent Method.
• Based on Application, market is studied across Blood & Blood Product, Cellular & Gene Therapy Product, Stem Cell Product, Tissues & Tissue Product, and Vaccines & Therapeutic.
• Based on End User, market is studied across Academic Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the global prevalence of chronic diseases
    • 5.1.1.2. Growing government support for pharmaceutical & biotechnology industries
    • 5.1.1.3. Rising number of new drug approvals
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the manufacture of biosimilar products
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological integrations in viral inactivation procedures
    • 5.1.3.2. Strong R&D investments in the life sciences industry
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulatory guidelines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Viral Inactivation Market, by Product

• 6.1. Introduction
• 6.2. Kits & Reagents
• 6.3. Services
• 6.4. Viral Inactivation Systems & Accessories

7. Viral Inactivation Market, by Method

• 7.1. Introduction
• 7.2. Pasteurization
• 7.3. Solvent Detergent Method

8. Viral Inactivation Market, by Application

• 8.1. Introduction
• 8.2. Blood & Blood Product
• 8.3. Cellular & Gene Therapy Product
• 8.4. Stem Cell Product
• 8.5. Tissues & Tissue Product
• 8.6. Vaccines & Therapeutic

9. Viral Inactivation Market, by End User

• 9.1. Introduction
• 9.2. Academic Research Institutes
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Viral Inactivation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Viral Inactivation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Viral Inactivation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. Charles River Laboratories International, Inc.
• 5. Cytiva by Danaher Corporation
• 6. Eurofins Scientific (Ireland) Limited
• 7. HiMedia Laboratories, LLC
• 8. Lonza Group Ltd.
• 9. Merck KGaA
• 10. Parker Hannifin Corporation
• 11. PromoCell GmbH
• 12. Rad Source Technologies, Inc.
• 13. Sartorius AG
• 14. Thermo Fisher Scientific Inc
• 15. WuXi AppTec Co., Ltd.